Esophageal squamous carcinoma molecular marker hsa-piR-20200 and application thereof
Through the molecular marker of esophageal squamous cell carcinoma hsa-piR-20200 and its related kits, the shortcomings of early diagnosis and treatment targets of esophageal squamous cell carcinoma have been solved, and the diagnosis and treatment effects with high specificity and sensitivity have been achieved, and the esophageal scaly patches have been improved. Prognosis evaluation and therapeutic effect of cancer.
Patent Information
- Application Number
- CN202411418899.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-12
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the prior art, the early diagnosis and treatment targets of esophageal squamous cell carcinoma are relatively limited, and the lack of reliable piRNAs biomarkers has affected the prognosis evaluation and treatment effect of esophageal squamous cell carcinoma.
A molecular marker of esophageal squamous cell carcinoma, hsa-piR-20200 and its related primer sets and detection kits are proposed to detect and diagnose esophageal squamous cell carcinoma in the early stage, and serve as a therapeutic target to inhibit the expression of hsa-piR-20200. Reagents for treatment.
The expression level of hsa-piR-20200 in esophageal squamous cell carcinoma is significantly higher than that of the adjacent tissues of cancer, with high clinical stage and patient survival correlation, providing a high specificity and sensitivity diagnostic method, and is a esophageal squamous cell carcinoma. Treatment provides new ideas.
Smart Images

Figure BDA0005080210860000091 
Figure BDA0005080210860000101 
Figure BDA0005080210860000112
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene engineering technology, and in particular to an esophageal squamous cell carcinoma molecular marker hsa-piR-20200 and an application thereof. Background Art
[0002] Esophageal cancer is one of the most common malignant tumors that seriously threatens human health. It has two main pathological types: squamous cell carcinoma and adenocarcinoma. Esophageal cancer generally has a poor prognosis, which is related to late detection and is closely related to tumor metastasis.
[0003] P-element-induced weak testis protein (PIWI)-interacting RNAs (piRNAs) are a class of small noncoding RNAs (ncRNAs) that were first discovered in the MILI protein of mouse testis in 2006. They are approximately 26-30 nt in length and are similar to microRNAs (miRNAs). piRNAs have long been considered the "dark matter" of ncRNAs in the genome, with regulatory functions in germline maintenance and transposon silencing.
[0004] Recent studies have shown that some piRNAs subgroups participate in the activation of oncogenes and the silencing of tumor suppressors in cancer through epigenetic mechanisms. These findings indicate that piRNAs may have important regulatory functions in the pathogenesis of tumors, but there are still limited reports on the relevance of piRNAs in the occurrence and development of esophageal squamous cell carcinoma, and there are few reports on the use of piRNAs as effective molecular markers.
[0005] Therefore, finding reliable piRNAs biomarkers for esophageal squamous cell carcinoma and using them as a basis for early diagnosis and a reliable therapeutic target has become an urgent problem to be solved by technicians in this field. Summary of the invention
[0006] In order to detect and diagnose esophageal squamous cell carcinoma at an early stage, evaluate the progression and prognosis of esophageal squamous cell carcinoma, and use it as a reliable treatment target, the present invention provides the following technical solutions:
[0007] The present invention provides an esophageal squamous cell carcinoma molecular marker hsa-piR-20200, the nucleotide sequence of the molecular marker is shown in SEQ ID NO.1.
[0008] The present invention also provides a primer set for detecting the above-mentioned molecular markers, the primer set comprising an upstream primer and a downstream primer, the nucleotide sequence of the upstream primer is shown in SEQ ID NO.2, and the nucleotide sequence of the downstream primer is shown in SEQ ID NO.3.
[0009] The present invention also provides a detection kit for esophageal squamous cell carcinoma molecular marker hsa-piR-20200, wherein the kit at least comprises the primer set as described above.
[0010] The present invention also provides the use of the esophageal squamous cell carcinoma molecular marker hsa-piR-20200, primer set or kit as described above in the preparation of one or more products for the diagnosis, treatment, staging and prognosis evaluation of esophageal squamous cell carcinoma.
[0011] The present invention also provides the use of the negatively regulating molecular marker hsa-piR-20200 as described above in the preparation of a drug for treating esophageal squamous cell carcinoma.
[0012] The present invention also provides a drug for treating esophageal squamous cell carcinoma, which comprises an agent for inhibiting the expression of the molecular marker hsa-piR-20200 according to claim 1.
[0013] Preferably, the reagent for inhibiting the expression of the molecular marker hsa-piR-20200 includes an hsa-piR-20200 inhibitor.
[0014] Preferably, the nucleotide sequence of the hsa-piR-20200 inhibitor is shown in SEQ ID NO. 8. The beneficial effects of the present invention are:
[0015] The present invention discloses an esophageal squamous cell carcinoma molecular marker hsa-piR-20200, the expression level of the hsa-piR-20200 molecular marker in the cancerous tissue of esophageal squamous cell carcinoma is significantly higher than that in the adjacent tissue, and its expression level is highly correlated with the clinical stage and the patient's survival period. It can be an effective means for early diagnosis, judgment of disease progression and prognosis evaluation of esophageal squamous cell carcinoma patients, and the molecular marker has strong specificity, high sensitivity and stable results for the diagnosis of esophageal squamous cell carcinoma, and has broad clinical application prospects.
[0016] This molecular marker opens up new ideas for the study of esophageal squamous cell carcinoma and can be an effective means for early diagnosis, judgment of clinical pathological progression and prognosis evaluation of esophageal squamous cell carcinoma patients. At the same time, this technology also provides reference and inspiration for the diagnosis of other malignant tumors and promotes the development of tumor molecular biology research. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.
[0018] Figure 1 To test the integrity of RNA and gDNA contamination in the sample and confirm the validity of the sample;
[0019] Figure 2The expression profiles of piRNAs in esophageal squamous cell carcinoma and adjacent tissues;
[0020] Figure 3 The differential expression of piRNAs in esophageal squamous cell carcinoma tissues and adjacent tissues;
[0021] Figure 4 are the piRNAs that are up-regulated and down-regulated in ESCC tissues;
[0022] Figure 5 To detect the expression level and relative difference value of piRNA in paired cancer tissues and adjacent paracancerous tissues using qRT-PCR method;
[0023] Figure 6 The expression of hsa-piR-20200 in 45 paired esophageal squamous cell carcinoma tissues and adjacent paracancerous tissues;
[0024] Figure 7 Based on Figure 6 The ROC curve drawn by the results;
[0025] Figure 8 To investigate the relationship between the expression of hsa-piR-20200 and the clinicopathological characteristics of patients with esophageal squamous cell carcinoma;
[0026] Fig. 9 The correlation between hsa-piR-20200 expression and TNM stage and patient prognosis;
[0027] Fig.10 The results of Kaplan-Meier survival analysis show the relationship between hsa-piR-20200 expression level and survival time of patients with esophageal squamous cell carcinoma.
[0028] Fig.11 The expression level of hsa-piR-20200 in five esophageal squamous cell carcinoma cell lines and human Het-1A cell line was detected by qRT-PCR;
[0029] Fig.12 is the expression level of hsa-piR-20200 after transfection of piRNA mimics or inhibitors into KYSE70 cells;
[0030] Fig.13 To investigate the relationship between overexpression and inhibition of hsa-piR-20200 and cancer cell proliferation in KYSE70 cell line;
[0031] Fig.14 To investigate the relationship between overexpression and inhibition of hsa-piR-20200 and cancer cell proliferation in KYSE180 cell line. DETAILED DESCRIPTION
[0032] The present invention provides an esophageal squamous cell carcinoma molecular marker hsa-piR-20200.
[0033] The nucleotide sequence of the molecular marker of the present invention is preferably as shown in SEQ ID NO.1; specifically: SEQ ID NO.1: 5′-ACCGTCGTAGTTCCGACCATAAACGATGCC-3′.
[0034] The present invention also provides a primer set for detecting the molecular marker as described above, the primer set comprising an upstream primer and a downstream primer. The nucleotide sequence of the upstream primer of the primer set of the present invention is preferably as shown in SEQ ID NO.2, and the nucleotide sequence of the downstream primer is preferably as shown in SEQ ID NO.3, specifically: SEQ ID NO.2: 5′-AACAATACCGTCGTAGTTCCGA-3′; SEQ ID NO.3: 5′-GTCGTATCCAGTAGGGT-3′
[0035] The present invention also provides a detection kit for esophageal squamous cell carcinoma molecular marker hsa-piR-20200, wherein the kit at least comprises the primer set as described above.
[0036] The kit of the present invention preferably also includes one or more of an RNA extraction reagent, an RNA reverse transcription reagent, and a qPCR amplification reagent. The RNA extraction reagent of the present invention preferably includes Trizol lysis solution, chloroform, isopropanol, 75% ethanol, and DEPC water; the RNA reverse transcription reagent preferably includes reverse transcriptase, DNA polymerase, DEPC water, gDNAEraser, RnaseFree dH2O, PrimerScript RT Enzyme Mix I, RTPrimerMix, and 5×gDNAEraserBuffer; the qPCR amplification reagent of the present invention preferably includes SYBRPremix Ex TaqTMII, ROC Reference Dye II, and RnaseFree dH2O.
[0037] The present invention also provides the use of the esophageal squamous cell carcinoma molecular marker hsa-piR-20200, primer set or kit as described above in the preparation of one or more products for the diagnosis, treatment, staging and prognosis evaluation of esophageal squamous cell carcinoma, preferably in the preparation of products for the diagnosis, treatment, staging or prognosis evaluation of esophageal squamous cell carcinoma; more preferably in the preparation of products for the diagnosis and staging of esophageal squamous cell carcinoma.
[0038] The present invention also provides an experimental application of negatively regulating the molecular marker hsa-piR-20200 as described above in the preparation of a drug for treating esophageal squamous cell carcinoma. The negative regulation of the present invention is preferably to inhibit the expression of the molecular marker hsa-piR-20200. The expression of the molecular marker hsa-piR-20200 inhibited by the sequence described in SEQ ID NO.8 is preferably to inhibit the expression of the molecular marker hsa-piR-20200.
[0039] The present invention also provides an experimental reagent for inhibiting esophageal squamous cell carcinoma, including a reagent for inhibiting the expression of the molecular marker hsa-piR-20200.
[0040] The reagent for inhibiting the expression of the molecular marker hsa-piR-20200 of the present invention preferably includes an hsa-piR-20200 inhibitor, and the hsa-piR-20200 inhibitor includes the nucleotide shown in SEQ ID NO.8, specifically: SEQ ID NO.8: 5'-TCTTCTTATGAGACCCCTTGACCA-3'.
[0041] In order to further illustrate the present invention, the technical solution provided by the present invention is described in detail below in conjunction with the accompanying drawings and embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0042] Case collection: Clinical tissue samples of patients undergoing esophageal squamous cell carcinoma surgery in the Department of Oncology, Nanjing Hospital Affiliated to Nanjing Medical University and Yancheng Cancer Hospital from 2015 to 2019 were collected. None of the patients had undergone radiotherapy or chemotherapy before surgery. A total of 45 groups of paired cancer tissues and corresponding paracancerous tissue samples were selected. Paracancerous tissue was normal esophageal mucosal tissue more than 5 cm away from the edge of the tumor. All samples were immediately put into liquid nitrogen after ex vivo, and then moved into an ultra-low temperature refrigerator at -80°C for long-term storage for future use. Patients were contacted and examined by doctors to calculate overall survival (OS). Patients were evaluated every 3 months in the first year, every 6 months in the second year, and once a year after surgery until October 2019. The date of death was obtained from outpatient and inpatient medical records or telephone follow-up.
[0043] All specimens in this experiment were obtained with informed consent signed by the patients or their agents, and all research involving human specimens was reviewed and approved by the Ethics Committee of Nanjing Hospital Affiliated to Nanjing Medical University and Yancheng Cancer Hospital.
[0044] The inclusion criteria for the study patients were as follows:
[0045] a. Confirmed as esophageal squamous cell carcinoma by postoperative pathology (clinical staging according to the 8th edition (2017) TNM staging criteria);
[0046] b. Patients who received radical or palliative resection during hospitalization, and those who received preoperative chemoradiotherapy were excluded;
[0047] c. The current medical history, family history, personal history and various examination data are complete.
[0048] In this study, 45 cases of esophageal squamous cell carcinoma and adjacent tissues were collected.
[0049] The clinical data collected mainly include the patient's name, gender, age, occupation, past medical history, family history, female menstrual history, and marital history. In addition to the above general information, it also includes clinical characteristics, including the histological type, location, size, degree of infiltration, lymph node metastasis, degree of tumor cell differentiation, tumor TNM stage, operation time, preoperative radiotherapy and chemotherapy, and routine auxiliary examinations. At the same time, the follow-up consent of all persons was obtained, and the examination results were fully preserved.
[0050] The data in this invention are expressed as mean ± standard deviation (SD), indicating the correlation between hsa-piR-20200 and clinical staging data and prognosis of patients with esophageal squamous cell carcinoma verified by t-test, one-way analysis of variance and survival analysis. All statistical analyses were performed using SPSS19.0 and GraphPadPrism 7. For all results, P < 0.05 was considered statistically significant.
[0051] Example 1
[0052] Five pairs of esophageal squamous cell carcinoma tissues and adjacent tissues were randomly selected from the collected samples. Shanghai Kangcheng Biotechnology Co., Ltd. used high-throughput chips to screen out differentially expressed piRNAs in esophageal squamous cell carcinoma and adjacent tissues. The results are as follows: Figures 1 to 5 shown.
[0053] The expression profile of piRNAs in esophageal squamous cell carcinoma was preliminarily evaluated by high-throughput microarray screening of piRNAs in 5 pairs of esophageal squamous cell carcinoma and adjacent tissues. Figure 1 As shown, the integrity of RNA and gDNA contamination were detected by denaturing agarose gel electrophoresis, and the validity of the eight samples was confirmed.
[0054] Depend on Figure 2 and Figure 4 As shown in the figure, a total of 394 piRNAs were differentially expressed between ESCC tissues and non-ESCC tissues by t-test. Among these 394 piRNAs, 273 were significantly upregulated in ESCC tissues, and 121 were significantly downregulated;
[0055] Depend on Figure 3 As shown, the fold change values and P values were obtained by differential analysis. When the biological replicates of a sample were ≥ 2, a volcano plot was drawn according to these two factors to show the differences between the two groups of samples.
[0056] Depend on Figure 5 As shown, the present invention selects 5 overexpressed piRNAs from high to low based on the multiple difference in expression between cancer tissue and adjacent paracancerous tissue. Subsequently, the expression levels of these dysregulated piRNAs in 10 pairs of esophageal squamous cell carcinoma tissues and non-cancerous tissues were analyzed by qRT-PCR method, and it was found that compared with the other 4 piRNAs, the expression of hsa-piR-20200 (DQ570513P) was significantly increased. Therefore, the present invention selects hsa-piR-20200 as a candidate target for esophageal squamous cell carcinoma for further research, in which hsa-piR-20200 is significantly highly expressed in esophageal squamous cell carcinoma tissue, screens out the molecule as a molecular marker closely related to esophageal squamous cell carcinoma, and further expands the sample verification.
[0057] Example 2
[0058] Specimen collection
[0059] After being removed from the body, the tissue samples were immediately rinsed with ice-cold physiological saline and then quickly placed in prepared numbered cryotubes with RNA protection solution added. The tightly capped cryotubes were quickly frozen in liquid nitrogen.
[0060] Extraction of total RNA
[0061] (1) Take 0.1 g of frozen tissue from the liquid nitrogen tank, grind it into powder with liquid nitrogen, and wash the powdered frozen tissue twice with pre-cooled PBS.
[0062] (2) Add 1 mL of Trizol lysis buffer to the frozen tissue powder, mix well by pipetting with a sterile enzyme-free pipette tip, let stand for 5 min, and transfer the lysis buffer into a pre-labeled 1.5 mL EP tube.
[0063] (3) Centrifuge the EP tube at 4°C, 7500 g for 5 min, take the supernatant, add chloroform equivalent to 1 / 5 of the volume of Trizol, shake and mix for 30 sec, and let it stand for 2 min.
[0064] (4) The mixed solution after standing in step (3) was centrifuged at 4°C and 12,000 g for 15 min. The solution after centrifugation was separated into three layers: aqueous phase, white precipitate layer and red organic layer. The aqueous phase was transferred to a newly marked 1.5 mL EP tube, and the white precipitate was avoided as much as possible.
[0065] (5) Add an equal volume of isopropanol to the aqueous phase, mix by inversion, let stand for 10 min, and then centrifuge at 4°C, 12,000 g for 10 min.
[0066] (6) Discard the supernatant obtained after centrifugation in step (5), add 1 mL of 75% ethanol to the precipitate, wash the RNA, precipitate, and centrifuge at 4°C, 7500 g for 5 min. Discard the supernatant after centrifugation. Remove the ethanol from the precipitate, and air-dry the precipitate at room temperature for 15 min. Finally, add 10-40 μL of DEPC water according to the amount of precipitate to dissolve the RNA precipitate to obtain total RNA.
[0067] RNA concentration and integrity determination
[0068] RNA concentration and purity were determined using a UV spectrophotometer.
[0069] Before measuring the concentration, adjust the total RNA to zero with DEPC water. Read the value at 260nm. When the value at 260nm is 1, it means the concentration is 40ng / μL. Take 1μL RNA solution and use a UV spectrophotometer to detect its absorbance at 260nm and 280nm, and record the OD 260 and OD 280 ratio.
[0070] A260 / A280 was used to detect RNA purity. A ratio ranging from 1.7 to 2.1 indicated that the requirements were met, otherwise re-extraction was performed.
[0071] RNA reverse transcription and qPCR amplification
[0072] (1) Configuration of reverse transcription system
[0073] Take out the reverse transcription kit from the -20℃ refrigerator, insert the enzyme in the kit into the ice box, melt other reagents on ice, and melt RNase Free H2O at room temperature for later use.
[0074] The volume of RNA and the volume of DEPC water required for reverse transcription in each tube were calculated based on the RNA concentration measured in Example 3. The total volume of RNA and DEPC water did not exceed 7 μL.
[0075] Note: RNA is easily degraded by repeated freezing and thawing. Once the RNA extracted from the sample is determined to be of good quality, it should be reverse transcribed into cDNA as much as possible at one time according to the cancer and adjacent paracancerous pairing standards. If the amount of RNA in the paired sample is large, exceeding the amount for reverse transcription of 10 copies, considering the cost of reverse transcription, reverse transcription can be performed on only 10 copies.
[0076] Place the PCR tube rack on ice, add sterile enzyme-free 200μL PCR tubes as needed, and mark them by number. After the pipette absorbs an appropriate amount of RNA, insert the tip of the pipette vertically into the bottom of the PCR tube, and gently and evenly pump out the liquid. After completion, confirm that there is no obvious residue on the tip of the pipette. Absorb an appropriate amount of DEPC water with the pipette, and slowly and evenly pump the tip of the pipette into the PCR tube against the back wall.
[0077] Using TaKaRa Kit PrimeScript TM RT reagent Kit with gDNA Eraser is used to reverse transcribe the extracted total RNA into cDNA. The kit contains gDNAEraser DNase, which can effectively remove contaminated genomic DNA.
[0078] The first step is to remove the genomic DNA reaction. The reaction system and conditions are shown in Table 1:
[0079] Table 1 Reaction system for genomic DNA removal
[0080] Reagents Usage 5×gDNAEraserBuffer 2.0μL gDNAEraser 1.0μL Total RNA 1.0 μg RNaseFreedH2O Add water to 10.0 μL
[0081] After adding the above reagents, place the PCR tube on an eight-tube centrifuge, gently flick off the bubbles at the bottom or wall of the tube, centrifuge for 10 to 20 seconds, then place it on an RT-PCR instrument and react at 42°C for 2 minutes. Place the reaction product on ice for later use.
[0082] Step 2: Reverse transcription: Take 1.5 mL of enzyme-free EP tube and prepare each tube of reaction mixture according to the following ratio:
[0083] Table 2 Reverse transcription reagents
[0084] Reagents Usage Reaction solution of step 1 10.0μL PrimeScriptRTEnzymeMixI 1.0μL RTPrimerMix 1.0μL 5×PrimeScriptBuffer2 4.0μL RNaseFreedH2O 4.0μL Total volume 20.0μL
[0085] Set the reaction conditions: 37℃ for 15min, 85℃ for 5sec, and maintain at 4℃. Remove the sample after the temperature drops to 4℃. The cDNA product synthesized by reverse transcription can be used directly for qPCR amplification, or stored at -20℃ (for use within 30 days).
[0086] (2) qPCR amplification
[0087] The present invention designs specific primers for detecting the molecular marker hsa-piR-20200, including an upstream primer and a downstream primer.
[0088] The upstream primer sequence is: SEQ ID NO.2: 5′-AACAATACCGTCGTAGTTCCGA-3′;
[0089] The downstream primer sequence is: SEQ ID NO.3: 5′-GTCGTATCCAGTAGGGT-3′;
[0090] Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control, and the sequence was:
[0091] GAPDH_F: SEQ ID NO.4: 5′-TGCACCACCAACTGCTTAGC-3′,
[0092] GAPDH_R: SEQ ID NO.5: 5′-GTCGTATCCAGTAGGGT-3′. Prepare an ice box, eight-tube strips and tube caps, an eight-tube strip rack, tweezers, sterile 1.5 mL EP tubes, an EP tube rack, a pipette with an appropriate range (2 μL and 20 μL are required ranges), and sterile film gloves.
[0093] Take out the cDNA, primers, and PCR reagents (SYBR Premix Ex TaqTMII, ROC Reference Dye II) of the sample to be tested from the -20℃ refrigerator and thaw on ice; first place the thawed cDNA, primers, and PCR reagents on an oscillator for a short oscillation, then place them in a centrifuge for a short centrifugation for 10-20 seconds, and place them on ice for later use.
[0094] Take a 1.5 mL enzyme-free EP tube and prepare eight tubes of PCRMix according to the following formula per well (prepare according to a total volume of 20 μL):
[0095] Table 3 PCR Mix Reagents
[0096] Reagents Usage SYBR Premix Ex TaqTM II 10.0uL ForwardPrimer / ReversePrimer 1.0μL ROCReferenceDye / II 0.4uL cDNA 1.0uL RNaseFreedH2O 7.6μL Total volume 20.0μL
[0097] The reaction conditions are as follows:
[0098] ABI 7300 / 7500 Real-time PCR System StepOnePlusTM;
[0099] Stage 1: 95°C for 30 seconds, 1 cycle;
[0100] The second stage: 95℃5sec, 60℃30-34sec, 40 cycles; the third stage: 95℃15sec, 60℃1min, 95℃5sec, 1 cycle;
[0101] According to the preset positions of each sample and duplicate well in the eight-tube strip, adjust the range of the 2μL pipette to 1μL, and add the cDNA of the samples in sequence.
[0102] Turn off the fluorescent light, shield all bright light sources, add the corresponding amount of ROC Reference Dye / II to the previously stationary EP tube containing PCRMix, then shake to mix, and centrifuge for 10-20 seconds to ensure that the aliquoted Mix is mixed.
[0103] Use a 20μL pipette to absorb the Mix and then pump the liquid against the back wall of the eight-tube strip in turn. After each pumping, make sure that there is no obvious residue on the tip of the gun; use tweezers to grab the edge of one side of the eight-tube cap and gently place it on the tube mouth. Wear new sterile film gloves, gently take the eight-tube strip together with the eight-tube rack out of the ice box and place it on the table, gently press one side of the tube cap to fix it, and then quickly tighten the tube cap with force. Mark both ends of the tube cap with a marker pen, then gently tap the bottom of both ends of the eight-tube strip from bottom to top, remove it from the tube rack, and place it on the eight-tube centrifuge rack. If there are bubbles, tap the bottom of the tube lightly, centrifuge for a short time, confirm that the liquid level of each tube is consistent and there are no bubbles in the tube, and then place it on ice.
[0104] Operate the ABI 7300 / 7500 real-time quantitative PCR instrument, set the reaction conditions, run the melting curve, and determine the target band through melting curve analysis and electrophoresis. ΔΔ The CT method was used for relative quantification, and the results were as follows Figures 6-7 shown.
[0105] The present invention uses cancer tissue and adjacent tissue samples from 45 patients with esophageal squamous cell carcinoma to verify the research results of the high-throughput human piRNAs chip in Example 1, and determines the expression of hsa-piR-20200 in 45 paired esophageal squamous cell carcinoma tissues and normal tissues by qRT-PCR method. Figure 6 The results showed that the expression of hsa-piR-20200 in squamous cell carcinoma tissues was significantly higher than that in paired adjacent cancer tissues.
[0106] In addition, according to the different expression levels of hsa-piR-20200 in cancer tissue and adjacent tissue, the present invention divides it into high expression and low expression. Among them, the expression level of hsa-piR-20200 in cancer tissue of 32 cases was higher than that in adjacent tissue. The present invention also draws the ROC curve to explore the diagnostic value of hsa-piR-20200 in distinguishing squamous cell carcinoma tissue and adjacent tumor tissue. The results are as follows Figure 7 As shown, the area under the ROC curve (AUC) is 0.7753, which shows that the detection result of the molecular marker hsa-piR-20200 in the present invention is authentic and has diagnostic value.
[0107] Considering the overexpression of hsa-piR-20200 in 45 patients with esophageal squamous cell carcinoma, in order to evaluate the correlation between hsa-piR-20200 expression or TNM staging and the prognosis of patients with esophageal squamous cell carcinoma, the present invention further studied the relationship between the expression of hsa-piR-20200 and the clinical pathological characteristics of patients with esophageal squamous cell carcinoma, and performed Kaplan-Meier survival analysis. The survival analysis results of patients 1 to 45 at different times are shown in Tables 4 to 5 and Figures 8 to 10 .
[0108] Table 4 Differences in the expression of hsa-piR-20200 in cancer tissues and adjacent tissues
[0109]
[0110]
[0111]
[0112] Note: Difference-N refers to the difference between cancer tissue and adjacent tissue; expression refers to the relative expression level;
[0113] Table 5 Staging and survival data of 45 patients with esophageal squamous cell carcinoma
[0114]
[0115]
[0116] From Tables 4 to 5 and Figure 8 The results showed that in patients with esophageal squamous cell carcinoma, the relative expression levels of hsa-piR-20200 in cancer and adjacent tissues were not associated with age, grade, or T stage. However, the upregulation of the relative expression level of hsa-piR-20200 was positively correlated with TNM stage (P=0.0006), lymph node metastasis (P=0.0006), and gender (P=0.0083).
[0117] According to Tables 4-5 and Fig. 9 The results showed that the higher the TNM stage of esophageal squamous cell carcinoma patients, the worse the prognosis.
[0118] According to Tables 4-5 and Fig.10 The results showed that the survival time of patients with higher relative expression levels of hsa-piR-20200 was significantly shorter than that of patients with lower expression levels.
[0119] These results suggest that hsa-piR-20200 may play a key role in the occurrence and development of esophageal squamous cell carcinoma and can be used as an independent biomarker in clinical practice to provide prognostic assessment.
[0120] Cell culture and transfection
[0121] The human normal esophageal cell line HET-1A, human ESCC cell lines KYSE30, KYSE70, KYSE140, KYSE180 and KYSE450 involved in this example were provided by Cao Xiufeng's experimental team of the Experimental Center of Nanjing Hospital Affiliated to Nanjing Medical University.
[0122] The above five cell lines were cultured in RPMI-1640 medium containing 10% fetal bovine serum and 1% penicillin-streptomycin at 37°C and 5% CO2. Lipofectamine 2000 was used to apply 50 nM hsa-piR-20200 mimics or inhibitors and negative controls (NC) to transfected KYSE70 and KYSE180 cell lines. Finally, the qRT-PCR method was used to measure the expression level of hsa-piR-20200 in five esophageal squamous cell carcinoma cell lines and the transfection efficiency of hsa-piR-20200. The results are shown in Table 6 and Table 6. Figures 11-12 shown.
[0123] The specific operation methods of cell RNA extraction and qRT-PCR are the same as those of esophageal cancer tissue specimens.
[0124] Specific primers for hsa-piR-20200, including upstream primers and downstream primers,
[0125] The upstream primer sequence is: SEQ ID NO.2: 5′-AACAATACCGTCGTAGTTCCGA-3′;
[0126] The downstream primer sequence is: SEQ ID NO.3: 5′-GTCGTATCCAGTAGGGT-3′;
[0127] Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control, and the sequence was:
[0128] GAPDH_F: SEQ ID NO.4: 5′-TGCACCACCAACTGCTTAGC-3′;
[0129] GAPDH_R: SEQ ID NO.5: 5′-GTCGTATCCAGTAGGGT-3′;
[0130] The negative control (NC) sequence is: SEQ ID NO.6: 5′-TTGCACGAGCGAAGCCGT-3′;
[0131] Table 6 Expression level and transfection efficiency of hsa-piR-20200 in esophageal squamous cell carcinoma cell lines
[0132]
[0133] The present invention also designs mimics and inhibitors for transfecting hsa-piR-20200, and the mimics and inhibitors are used to upregulate or inhibit the expression of hsa-piR-20200 in human esophageal squamous cell carcinoma cell lines KYSE70 and KYSE180, respectively.
[0134] Sequence of piRNA mimic:
[0135] SEQ ID NO.7: 5'-TGGTCAAGGGGTCTCATAAGAAGA-3';
[0136] Sequence of piRNA inhibitor:
[0137] SEQ ID NO. 8: 5'-TCTTCTTATGAGACCCTTGACCA-3'.
[0138] The expression levels of hsa-piR-20200 in five esophageal squamous cell carcinoma cell lines were detected by qRT-PCR. Figures 11-12 The results showed that hsa-piR-20200 was highly expressed in KYSE70 and KYSE180 cells compared with normal cell lines. KYSE70 cells were transfected with piRNA mimics or inhibitors using Lipofectamine 2000 transfection reagent, and after 48 hours of treatment, hsa-piR-20200 expression could be significantly upregulated or inhibited.
[0139] CCK-8 cell proliferation assay
[0140] KYSE70 and KYSE180 cells were transfected with NC, mimics or inhibitors and cultured at 37°C. Then, 10 μL of CCK-8 solution was added to each well and incubated for 2 hours. The absorbance of each well was measured at 490 nm using a microplate reader on days 0, 1, 2, 3 and 4 after inoculation. All experiments were performed at least three times, and the results are shown in Tables 7 and Figures 13-14 shown.
[0141] Table 7 Absorbance of NC, KYSE70 and KYSE180 cells after transfection
[0142]
[0143] From Table 7 and Figures 13-14 The results showed that the proliferation ability of KYSE70 and KYSE180 cells was detected by CCK-8. Inhibition of hsa-piR-20200 can significantly reduce cell proliferation, while overexpression of hsa-piR-20200 has the opposite effect. It can be seen that inhibiting the expression of hsa-piR-20200 can treat esophageal squamous cell carcinoma or inhibit the development of esophageal squamous cell carcinoma, and hsa-piR-20200 can be used as a therapeutic target for esophageal squamous cell carcinoma.
[0144] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.
Claims
1. A molecular marker for esophageal squamous cell carcinoma hsa-piR-20200, characterized in that: The nucleotide sequence of the molecular marker is shown in SEQ ID NO.
1.
2. A primer set for detecting the molecular marker according to claim 1, characterized in that: The primer set includes an upstream primer and a downstream primer. The nucleotide sequence of the upstream primer is shown in SEQ ID NO.2, and the nucleotide sequence of the downstream primer is shown in SEQ ID NO.
3.
3. A detection kit for esophageal squamous cell carcinoma molecular marker hsa-piR-20200, characterized in that: The kit comprises the primer set as claimed in claim 2.
4. Use of the esophageal squamous cell carcinoma molecular marker hsa-piR-20200 according to claim 1, the primer set according to claim 2, or the kit according to claim 3 in the preparation of one or more products for diagnosis, treatment, staging assessment and prognosis assessment of esophageal squamous cell carcinoma.
5. Use of the molecular marker hsa-piR-20200 described in negative regulation claim 1 in the preparation of drugs for treating esophageal squamous cell carcinoma.
6. A drug for treating esophageal squamous cell carcinoma, characterized in that: The drug includes an agent that inhibits the expression of the molecular marker hsa-piR-20200 described in claim 1.
7. The drug for treating esophageal squamous cell carcinoma according to claim 6, characterized in that: The reagent that inhibits the expression of the molecular marker hsa-piR-20200 includes an hsa-piR-20200 inhibitor.
8. The drug according to claim 7, characterized in that The hsa-piR-20200 inhibitor includes the nucleotide shown in SEQ ID NO.8.
